NCT02879669View on ClinicalTrials.gov

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

May 31, 2020

Conditions
To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
Interventions
BIOLOGICAL

ONCOS-102

DRUG

Pemetrexed/cisplatin (carboplatin)

DRUG

Cyclophosphamide

Trial Locations (7)

Unknown

Centre Georges-François Leclerc, Dijon

CHU de Rennes - Pontchaillou, Rennes

Hospital Universitario Quirón, Barcelona

Vall d'Hebron Univerity Hospital, Barcelona

Hospital Universitari de Girona Doctor Josep Trueta - Institut Català d'Oncologia, Girona

Hospital 12 de octubre, Madrid

Hospital Universitario HM Sanchinarro, Madrid

Sponsors

Collaborators (1)

Theradex
All Listed Sponsors
collaborator

Theradex

INDUSTRY

lead

Targovax Oy

INDUSTRY

NCT02879669 - A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma | Biotech Hunter | Biotech Hunter